Bial: peers
Bial beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Bial, Pestana Hotel Group, Grifols, S.A., Amplifon S.p.A., Stevanato Group S.p.A., DiaSorin S.p.A., Laboratorios Farmaceuticos Rovi, S.A., Almirall, S.A.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Bialbase 🇵🇹 PT Percentile in Healthcare Percentile in Portugal | Pestana Hotel Group 🇵🇹 PT Percentile in Healthcare Percentile in Portugal | Grifols, S.A. GRF.MC · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | Amplifon S.p.A. AMP.MI · 🇮🇹 IT Percentile in Healthcare Percentile in Italy | Stevanato Group S.p.A. STVN · 🇮🇹 IT Percentile in Healthcare Percentile in Italy | DiaSorin S.p.A. DIA.MI · 🇮🇹 IT Percentile in Healthcare Percentile in Italy | Laboratorios Farmaceuticos Rovi, S.A. ROVI.MC · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | Almirall, S.A. ALM.MC · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | —— | —— | $7.9 BAug 1, 2026 · Market data1st of 6 | $7.7 Blast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 6 | $6.4 BAug 1, 2026 · Market data3rd of 6 | $4.3 BAug 1, 2026 · Market data4th of 6 | $3.6 BAug 1, 2026 · Market data5th of 6 | $2.0 Blast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 6 | $5.4 B6 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $769 MFY2025 · Wikidata7th of 7 | $8.5 BFY2025 · ESEF1st of 7 | $2.7 BFY2025 · ESEF2nd of 7 | $1.3 BFY2025 · SEC4th of 7 | $1.3 BFY2025 · ESEF3rd of 7 | $838 MFY2025 · ESEF6th of 7 | $1.2 BFY2025 · ESEF5th of 7 | $1.3 B7 ranked |
| Net income (Higher is better) | —— | $175 MFY2025 · Wikidata2nd of 7 | $453 MFY2025 · ESEF1st of 7 | $103 MFY2025 · ESEF6th of 7 | $158 MFY2025 · SEC5th of 7 | $175 MFY2025 · ESEF3rd of 7 | $158 MFY2025 · ESEF4th of 7 | $52 MFY2025 · ESEF7th of 7 | $158 M7 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | 26,314As on 2022 · Profile1st of 5 | 11,265As on 2020 · Profile2nd of 5 | 6,010December 31, 2025 · Profile3rd of 5 | 1,939As on 2022 · Profile4th of 5 | —— | 1,7732019 · Profile5th of 5 | 6,0105 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | +8.7%FY2025 · ESEF3rd of 647th54th | +3.6%FY2025 · ESEF5th of 633rd37th | +12.0%FY2025 · SEC2nd of 654th71st | +5.0%FY2025 · ESEF4th of 637th44th | +1.4%FY2025 · ESEF6th of 629th31st | +17.1%FY2025 · ESEF1st of 663rd76th | +6.8%6 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | +9.0%FY2025 · SEConly one with it50th— | ———— | ———— | ———— | +9.0%— |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | -34.5%FY2025 · ESEF5th of 514th16th | +23.6%FY2025 · SEC2nd of 567th67th | -11.4%FY2025 · ESEF4th of 526th26th | +7.3%FY2025 · ESEF3rd of 547th36th | +358.4%FY2025 · ESEF1st of 596th99th | +7.3%5 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | 38.0%FY2025 · ESEF2nd of 323rd39th | ———— | 29.0%FY2025 · SEC3rd of 315th39th | 64.7%FY2025 · ESEF1st of 359th80th | ———— | ———— | 38.0%3 ranked |
| Operating margin (Higher is better) | ———— | ———— | 16.5%FY2025 · ESEF4th of 684th69th | 8.2%FY2025 · ESEF5th of 670th48th | 16.8%FY2025 · SEC3rd of 684th80th | 19.1%FY2025 · ESEF2nd of 687th83rd | 25.0%FY2025 · ESEF1st of 692nd84th | 6.6%FY2025 · ESEF6th of 667th36th | 16.6%6 ranked |
| Net margin (Higher is better) | ———— | 22.8%FY2025 · Wikidata1st of 791st86th | 5.3%FY2025 · ESEF5th of 770th50th | 3.8%FY2025 · ESEF7th of 768th38th | 11.8%FY2025 · SEC4th of 782nd80th | 13.0%FY2025 · ESEF3rd of 783rd81st | 18.9%FY2025 · ESEF2nd of 789th88th | 4.2%FY2025 · ESEF6th of 768th45th | 11.8%7 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | 10.4%FY2025 · ESEF5th of 672nd72nd | 15.0%FY2025 · ESEF3rd of 681st77th | 1.9%FY2025 · SEC6th of 656th20th | 23.5%FY2025 · ESEF1st of 692nd84th | 16.4%FY2025 · ESEF2nd of 682nd85th | 12.6%FY2025 · ESEF4th of 676th74th | 13.8%6 ranked |
| Return on equity (Higher is better) | ———— | ———— | 5.1%FY2025 · ESEF5th of 676th37th | 8.7%FY2025 · ESEF4th of 679th47th | 9.8%FY2025 · SEC2nd of 680th55th | 9.4%FY2025 · ESEF3rd of 680th53rd | 22.6%FY2025 · ESEF1st of 692nd85th | 3.2%FY2025 · ESEF6th of 675th24th | 9.1%6 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | 16.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 40.4׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 23.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 22.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | —— |
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | 0.9׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 4.8׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 3.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 4.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | —— |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | 0.9׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 3.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 2.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 4.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | —— |
| Free cash flow yield (Higher is better) | ———— | ———— | 11.2%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 0.4%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 7.3%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 3.8%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | —— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 1 of 1FY2025 · Scorecard1st of 7 | 4 of 6FY2025 · Scorecard5th of 7 | 3 of 5FY2025 · Scorecard6th of 7 | 10 of 12FY2025 · Scorecard3rd of 7 | 3 of 5FY2025 · Scorecard6th of 7 | 5 of 5FY2025 · Scorecard1st of 7 | 4 of 5FY2025 · Scorecard4th of 7 | 80% passed7 ranked |
| Growth checks (Higher is better) | —— | —— | 1 of 2FY2025 · Scorecard4th of 6 | 1 of 2FY2025 · Scorecard4th of 6 | 6 of 6FY2025 · Scorecard1st of 6 | 1 of 2FY2025 · Scorecard4th of 6 | 2 of 2FY2025 · Scorecard1st of 6 | 2 of 2FY2025 · Scorecard1st of 6 | 75% passed6 ranked |
| Profitability checks (Higher is better) | —— | 1 of 1FY2025 · Scorecard1st of 7 | 2 of 3FY2025 · Scorecard3rd of 7 | 2 of 3FY2025 · Scorecard3rd of 7 | 3 of 5FY2025 · Scorecard7th of 7 | 2 of 3FY2025 · Scorecard3rd of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 2 of 3FY2025 · Scorecard3rd of 7 | 67% passed7 ranked |
| Financial health checks (Higher is better) | —— | —— | 1 of 1FY2025 · Scorecard1st of 2 | —— | 1 of 1FY2025 · Scorecard1st of 2 | —— | —— | —— | 100% passed2 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | 14.9%2026-Q2 · 13F1st of 2 | —— | 14.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | —— | 14.6%2 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | 1652026-Q2 · 13F1st of 2 | —— | 1312026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | —— | 1482 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | -0.7 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | —— | —— | —— | -0.7 pp— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Bial: How market caps are worked out; Pestana Hotel Group: How market caps are worked out; Grifols, S.A.: How market caps are worked out; Amplifon S.p.A.: How market caps are worked out; Stevanato Group S.p.A.: How market caps are worked out; DiaSorin S.p.A.: How market caps are worked out; Laboratorios Farmaceuticos Rovi, S.A.: How market caps are worked out; Almirall, S.A.: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Bial | — | — | — |
| Pestana Hotel Group | — | — | — |
| Grifols, S.A. | 16.5%FY2025 | 84th percentile in Healthcaremedian -7.7%, 674 companies | 69th percentile in Spainmedian 9.2%, 79 companies |
| Amplifon S.p.A. | 8.2%FY2025 | 70th percentile in Healthcaremedian -7.7%, 674 companies | 48th percentile in Italymedian 8.8%, 101 companies |
| Stevanato Group S.p.A. | 16.8%FY2025 | 84th percentile in Healthcaremedian -7.7%, 674 companies | 80th percentile in Italymedian 8.8%, 101 companies |
| DiaSorin S.p.A. | 19.1%FY2025 | 87th percentile in Healthcaremedian -7.7%, 674 companies | 83rd percentile in Italymedian 8.8%, 101 companies |
| Laboratorios Farmaceuticos Rovi, S.A. | 25.0%FY2025 | 92nd percentile in Healthcaremedian -7.7%, 674 companies | 84th percentile in Spainmedian 9.2%, 79 companies |
| Almirall, S.A. | 6.6%FY2025 | 67th percentile in Healthcaremedian -7.7%, 674 companies | 36th percentile in Spainmedian 9.2%, 79 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Bial | Pestana Hotel Group | Grifols, S.A. | Amplifon S.p.A. | Stevanato Group S.p.A. | DiaSorin S.p.A. | Laboratorios Farmaceuticos Rovi, S.A. | Almirall, S.A. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $769 MWD7th | $8.5 BESEF1st | $2.7 BESEF2nd | $1.3 BSEC4th | $1.3 BESEF3rd | $838 MESEF6th | $1.2 BESEF5th |
| 2024 | — | — | $7.8 BESEF1st | $2.6 BESEF2nd | $1.2 BSEC4th | $1.3 BESEF3rd | $827 MESEF6th | $1.1 BESEF5th |
| 2023 | — | — | $7.1 BESEF1st | — | $1.2 BSEC2nd | — | — | — |
| 2022 | — | — | — | — | $1.0 BSEC | — | — | — |
| 2021 | — | — | — | — | $998 MSEC | — | — | — |
| 2020 | — | — | $6.1 BWD1st | — | $755 MSEC2nd | — | — | — |
| 2019 | — | — | — | — | $601 MSEC2nd | — | — | $957 MWD1st |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Bial#
Companies of the same industry first, then the same sector, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Pestana Hotel Group🇵🇹 PortugalSame sector: Healthcare · Same country: Portugal · Ratios of the last two fiscal years on filerevenue $768 M (fiscal 2025)45 of 100 (industry or sector 25 + country 15 + figures on file 5)In the group
- Grifols, S.A.GRF.MC · 🇪🇸 SpainSame sector: Healthcare (Pharmaceutical) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $7.9 B (Aug 1, 2026) · revenue $8.9 B (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)In the group
- Amplifon S.p.A.AMP.MI · 🇮🇹 ItalySame sector: Healthcare (Medical Instruments) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $7.7 B (last known, Jan 5, 2024) · revenue $2.7 B (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)In the group
- Stevanato Group S.p.A.STVN · 🇮🇹 ItalySame sector: Healthcare (Medical Instruments) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $6.4 B (Aug 1, 2026) · revenue $1.3 B (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)In the group
- DiaSorin S.p.A.DIA.MI · 🇮🇹 ItalySame sector: Healthcare (Diagnostics and Research) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $4.3 B (Aug 1, 2026) · revenue $1.4 B (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)In the group
- Laboratorios Farmaceuticos Rovi, S.A.ROVI.MC · 🇪🇸 SpainSame sector: Healthcare (Biotechnology) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $3.6 B (Aug 1, 2026) · revenue $838 M (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)In the group
- Almirall, S.A.ALM.MC · 🇪🇸 SpainSame sector: Healthcare (Pharmaceutical) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $2.0 B (last known, Jan 5, 2024) · revenue $1.2 B (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)In the group
- Faes Farma, S.A.FAE.MC · 🇪🇸 SpainSame sector: Healthcare (Pharmaceutical) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $1.7 B (Aug 1, 2026) · revenue $688 M (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)+ Add
- EL.En. S.p.A.ELN.MI · 🇮🇹 ItalySame sector: Healthcare (Medical Devices) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $1.9 B (Aug 1, 2026) · revenue $673 M (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)+ Add
- Philogen S.p.A.PHIL.MI · 🇮🇹 ItalySame sector: Healthcare · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $934 M (Aug 1, 2026) · revenue $361 M (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)+ Add
- Pharma Mar, S.A.PHM.MC · 🇪🇸 SpainSame sector: Healthcare (Biotechnology) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $2.1 B (Aug 1, 2026) · revenue $250 M (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)+ Add
- Pharmanutra S.p.A.PHN.MI · 🇮🇹 ItalySame sector: Healthcare (Pharmaceutical) · Same region: Southern Europe · Ratios of the last two fiscal years on fileMarket cap $593 M (last known, Jan 5, 2024) · revenue $148 M (year to December 2025)37 of 100 (industry or sector 25 + country 7 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.